Herring Omega-3 Density — EPA and DHA per Serving

Atlantic herring delivers approximately 1.7–2.0 g of combined EPA + DHA per 100 g serving, placing it consistently in the top three fish for marine omega-3 density alongside mackerel (2.5–2.7 g) and sardines (1.4–1.5 g). A single 4 oz serving (113 g) of herring supplies more EPA + DHA than 30 standard 1,000 mg fish oil softgel capsules — making it one of the most efficient dietary delivery vehicles for the omega-3 fatty acids that drive cardioprotective, anti-inflammatory, and neurocognitive effects documented across 40 years of clinical trial evidence.

Table of Contents

  1. Nutrient Density: Herring vs Other Fish and Supplements
  2. EPA vs DHA: Distinct Molecules, Distinct Roles
  3. Bypassing the ALA-to-EPA Bottleneck
  4. Cardiovascular Evidence: GISSI, REDUCE-IT, VITAL
  5. Inflammation Resolution and Specialized Pro-Resolving Mediators
  6. Neurocognitive Effects of DHA
  7. Dose Translation: Servings per Week
  8. Whole-Food Fish vs Fish Oil Supplements
  9. Oxidation, Storage, and Lipid Quality
  10. Key Research Papers
  11. Connections

Nutrient Density: Herring vs Other Fish and Supplements

Marine omega-3 density per 100 g cooked serving, drawn from USDA FoodData Central and matched literature:

  1. Atlantic mackerel — ~2,670 mg EPA + DHA per 100 g
  2. Atlantic herring — ~1,729 mg EPA + DHA per 100 g (Pacific: ~1,810 mg)
  3. Sardines (canned in oil) — ~1,480 mg EPA + DHA per 100 g
  4. Wild Atlantic salmon — ~1,840 mg EPA + DHA per 100 g; farmed Atlantic: ~2,260 mg
  5. Anchovies (canned in oil) — ~2,055 mg EPA + DHA per 100 g
  6. Rainbow trout — ~840 mg EPA + DHA per 100 g
  7. Albacore tuna (canned) — ~860 mg EPA + DHA per 100 g
  8. Cod (Atlantic) — ~158 mg EPA + DHA per 100 g
  9. Tilapia — ~115 mg EPA + DHA per 100 g

For comparison, a typical 1,000 mg fish oil capsule contains 180 mg EPA + 120 mg DHA = 300 mg combined omega-3. A 100 g serving of herring thus delivers the equivalent omega-3 of roughly six 1,000 mg fish oil capsules — without the rancidity, encapsulation cost, or pill burden. A 4 oz (113 g) restaurant-style serving roughly doubles that to 1,950 mg, exceeding the American Heart Association recommendation of 1,000 mg/day for patients with established coronary heart disease in a single serving.

Back to Table of Contents

EPA vs DHA: Distinct Molecules, Distinct Roles

EPA (eicosapentaenoic acid, 20:5n-3) and DHA (docosahexaenoic acid, 22:6n-3) are often referenced jointly as "marine omega-3," but they are structurally and functionally distinct:

  1. EPA — 20-carbon backbone, 5 double bonds. Serves as substrate for the 3-series prostaglandins and 5-series leukotrienes, which are markedly less inflammatory than the AA-derived 2-series prostaglandins and 4-series leukotrienes. EPA is also the precursor to the E-series resolvins. EPA appears to drive most of the cardiovascular and triglyceride-lowering effects of marine omega-3.
  2. DHA — 22-carbon backbone, 6 double bonds. Selectively incorporated into neural and retinal phospholipids; DHA accounts for ~30–40% of the fatty acid composition of brain gray matter phospholipids and ~60% of photoreceptor outer-segment phospholipids. Substrate for D-series resolvins and protectins. DHA drives most of the neurocognitive and visual development effects.

Herring delivers EPA and DHA in roughly equal proportion (typically 700–900 mg each per 100 g), making it a balanced source for both effect categories. By contrast, krill oil is EPA-heavy with much less DHA, and algae-derived supplements are typically DHA-dominant with minimal EPA.

Back to Table of Contents

Bypassing the ALA-to-EPA Bottleneck

The plant-source omega-3 alpha-linolenic acid (ALA, 18:3n-3, found in flaxseed, walnuts, and chia) must be elongated and desaturated in vivo to produce EPA and DHA. The pathway requires the delta-6 desaturase enzyme (FADS2), elongase enzymes, and the delta-5 desaturase — with the same enzymatic machinery shared by the competing n-6 pathway converting linoleic acid to arachidonic acid.

Conversion efficiency in adults is poor:

The practical implication is that consuming 10 g of ALA from flaxseed delivers an expected 0.5 g of EPA and 0–1 g of DHA, with high inter-individual variation driven by FADS gene polymorphisms. The same gram of EPA + DHA from herring requires no conversion and is incorporated into cell membranes within hours of consumption. For individuals with the FADS1 rs174537 minor allele (common in populations of European ancestry), conversion efficiency is further reduced, making direct dietary EPA + DHA from fish particularly important.

Back to Table of Contents

Cardiovascular Evidence: GISSI, REDUCE-IT, VITAL

The cardiovascular omega-3 trial landscape includes both landmark positive studies and recent null trials that have refined the indication:

  1. GISSI-Prevenzione (1999) — 11,324 Italian post-MI patients randomized to 1 g/day EPA + DHA, Vitamin E, both, or neither for 3.5 years. The omega-3 arm showed a 20% reduction in all-cause mortality, 30% reduction in cardiovascular death, and 45% reduction in sudden cardiac death. The study established secondary-prevention omega-3 as a class IIa AHA recommendation.
  2. JELIS (2007) — 18,645 Japanese hypercholesterolemic patients randomized to statin + 1.8 g/day EPA vs statin alone. The EPA arm showed a 19% reduction in major coronary events.
  3. REDUCE-IT (2019) — 8,179 patients with established CVD or diabetes + elevated triglycerides randomized to icosapent ethyl (4 g/day purified EPA) vs mineral oil placebo. The EPA arm showed a 25% reduction in major adverse cardiovascular events at 4.9 years — the largest cardiovascular benefit of any omega-3 trial to date, driven by purified EPA at a pharmacological dose.
  4. VITAL (2019) — 25,871 US adults randomized to 1 g/day EPA + DHA for primary prevention. The trial was null for the composite cardiovascular endpoint but showed a 28% reduction in MI as a secondary endpoint, and a 17% reduction in CV events in participants consuming <1.5 servings of fish per week at baseline.
  5. STRENGTH (2020) — 13,078 patients randomized to a mixed EPA + DHA carboxylic acid formulation vs corn oil placebo. The trial was null, raising questions about whether the REDUCE-IT effect was driven by pure EPA specifically (vs mixed EPA + DHA) or by an unfavorable mineral oil placebo effect.

The 2021 American Heart Association Science Advisory continues to recommend two servings per week of oily fish for cardiovascular health, with the strongest evidence in secondary prevention and in patients with elevated triglycerides.

Back to Table of Contents

Inflammation Resolution and Specialized Pro-Resolving Mediators

The traditional model of omega-3 anti-inflammatory action emphasized competitive substrate displacement at the cyclooxygenase and lipoxygenase enzymes — EPA-derived 3-series prostaglandins are less inflammatory than AA-derived 2-series prostaglandins. Charles Serhan's laboratory at Harvard reframed the mechanism beginning in the early 2000s with the discovery of specialized pro-resolving mediators (SPMs), a family of lipid signaling molecules synthesized from EPA and DHA that actively terminate inflammation rather than passively reducing it.

SPM families include:

The clinical implication is that adequate dietary EPA + DHA is not just an "anti-inflammatory" intervention — it is a substrate requirement for the active resolution phase that follows acute inflammation. Inadequate SPM synthesis is implicated in the chronic, non-resolving inflammation that characterizes atherosclerosis, periodontal disease, and rheumatoid arthritis.

Back to Table of Contents

Neurocognitive Effects of DHA

DHA accounts for 30–40% of phospholipid fatty acids in the gray matter of the cerebral cortex and 60% of phospholipid fatty acids in retinal photoreceptor outer segments. Dietary DHA crosses the blood-brain barrier via the MFSD2A transporter as lysophosphatidylcholine-DHA and is incorporated into neural membrane phospholipids over a timescale of weeks to months.

Functional implications:

Back to Table of Contents

Dose Translation: Servings per Week

The 2020–2025 US Dietary Guidelines recommend 8 oz (227 g) of seafood per week for the general adult, with at least one of the servings being a low-mercury oily fish. The American Heart Association recommends two 3.5-oz (100 g) servings per week of oily fish for cardiovascular health. Translating those targets to herring:

  1. For general health — one 100 g serving of herring per week supplies approximately 1.7 g of EPA + DHA, equivalent to a daily dose of 250 mg — matching the EFSA adequate intake recommendation for adults.
  2. For cardiovascular secondary prevention — two 100 g servings of herring per week supplies approximately 500 mg/day of EPA + DHA, in the range of the GISSI-Prevenzione effective dose.
  3. For triglyceride lowering (3–4 g/day target) — dietary herring alone cannot reach the pharmacological dose; combination of two weekly servings with prescription icosapent ethyl or omega-3 ethyl esters is typically required.
  4. For pregnancy and lactation — the FDA "best choices" list recommends 8–12 oz/week of low-mercury fish; herring is explicitly listed as a safe choice.

Back to Table of Contents

Whole-Food Fish vs Fish Oil Supplements

Whole-food fish has several advantages over fish oil supplements that are not captured in the EPA + DHA gram-equivalent comparison:

The 2018 Cochrane systematic review of omega-3 supplement trials versus dietary fish suggested that the cardiovascular benefit attaches more clearly to whole-fish consumption than to capsule supplementation, although the comparison is confounded by other dietary co-variates.

Back to Table of Contents

Oxidation, Storage, and Lipid Quality

The 5 and 6 double bonds in EPA and DHA make them highly susceptible to peroxidation. Best-practice handling preserves the omega-3 yield of herring:

Back to Table of Contents

Key Research Papers

  1. GISSI-Prevenzione Investigators, dietary supplementation with omega-3 polyunsaturated fatty acids and vitamin E after myocardial infarction (Lancet 1999) — PubMed 10465168
  2. Bhatt DL et al., REDUCE-IT cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (NEJM 2019) — PubMed 30415628
  3. Manson JE et al., VITAL marine n-3 fatty acids and prevention of cardiovascular disease and cancer (NEJM 2019) — PubMed 30415637
  4. Yokoyama M et al., JELIS effects of EPA on major coronary events in hypercholesterolaemic patients (Lancet 2007) — PubMed 17398308
  5. Nicholls SJ et al., STRENGTH effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (JAMA 2020) — PubMed 33190147
  6. Serhan CN, pro-resolving lipid mediators are leads for resolution physiology (Nature 2014) — PubMed 24899309
  7. Burdge GC and Calder PC, conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults (Reprod Nutr Dev 2005) — PubMed 16215393
  8. Yurko-Mauro K et al., MIDAS beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline (Alzheimers Dement 2010) — PubMed 20434961
  9. Hibbeln JR et al., ALSPAC maternal seafood consumption in pregnancy and neurodevelopmental outcomes (Lancet 2007) — PubMed 17307104
  10. Hu FB et al., fish and omega-3 fatty acid intake and risk of coronary heart disease in women (JAMA 2002) — PubMed 11926894
  11. Mozaffarian D and Rimm EB, fish intake, contaminants, and human health (JAMA 2006) — PubMed 17047219
  12. Calder PC, omega-3 polyunsaturated fatty acids and inflammatory processes (Biochim Biophys Acta 2015) — PubMed 25149823

Back to Table of Contents

Connections

Back to Table of Contents